Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1339 - Assessment of Chemotherapy Induced Febrile Neutropenia in Cancer Patients - A Prospective Observational Study in South India (509P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Supportive Care and Symptom Management


Uday Venkat Mateti


Annals of Oncology (2017) 28 (suppl_10): x155-x165. 10.1093/annonc/mdx676


U.V. Mateti1, A.M. Sebastian1, M.L. Philip1, N. Saj1, V. Shetty2

Author affiliations

  • 1 Department Of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte University, 575018 - Mangaluru/IN
  • 2 Department Of Medical Oncology, K.S. Hegde Medical Academy, Justice K.S. Hegde Charitable Hospital, Nitte University, 575018 - Mangaluru/IN


Abstract 1339


Chemotherapy induced febrile neutropenia (CIFN) is an adverse drug reaction which needs medical attention. The treatment options for CIFN are mandatory to improve treatment outcomes and quality of life. The aim of the study is to evaluate the incidence, causality, severity, preventability, predictability and to analyze the outcomes of CIFN in cancer patients.


A prospective observational study was conducted in the in-patients and out-patients of oncology department who received chemotherapy within the period of October 2016 to March 2017. The information such as demographics (age, gender, co-morbidities), complaints on admission, hematological investigations [neutrophil counts, platelet counts, hemoglobin levels, ESR, WBC], type of tumor, stage of cancer, prophylaxis, cycle of antineoplastic chemotherapy that cause FN, treatment history and outcome data were obtained from the patient’s clinical record. Multinational Association for Supportive Care in Cancer score and Absolute Neutrophil Count grading was used to predict the patient’s risk of developing CIFN.


Out of 200 patients, 19 patients developed 22 episodes of CIFN. The overall occurrence of CIFN during the study period was 9.5%. The higher incidence of CIFN has been observed among male gender (57.89%), age group between 45-60 years (52.63%), stage III patients (42.10%), solid tumor (73.68%) and double chemotherapy regimen (59.1%). The higher incidence of CIFN was developed in I cycle (36.36%) followed by II cycle (22.72%) and VI cycle (18.18%). The length of hospitalization has been prolonged for all patients who developed CIFN with 6 median numbers of days.


As per the WHO and Naranjo’s scales most of the CIFN reactions were classified as probable 81.82% and 77.2% respectively. Out of 22 CIFN cases, 9.09% of mortality has been reported and all the CIFN reactions were predictable. In the 19 CIFN patients, there has no significant effect of prophylaxis to prevent the FN.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.